Interview of patients with HR+/HER2- metastatic breast cancer who received capivasertib + fulvestrant

Exclusion Criteria

• (self-reported):
• - Patients who had discontinued capivasertib for more than 6 months before the date of the interview
• - Unable or unwilling to follow study procedures (including providing informed consent)
• - Not proficient in spoken English, as assessed by the moderator
• - Receiving capivasertib in a clinical trial setting
• - Patients who are not able to recall instruction for administration of capivasertib in a manner consistent with the labeling (e.g. 4 days on followed by 3 days off)